


ROBUST PIPELINE OF SWITCH-CONTROL KINASE INHIBITORS

		RESEARCH	IND-ENABLING	PHASE 1	PHASE 1/2	PHASE 3	REGULATORY SUBMISSION	APPROVED
QINLOCK¹ (ripretinib) 50mg tablets KIT Inhibitor	GIST ≥4 th Line	Phase 3 Planned for 2H 2023 ⁴						 + Global Approvals ³
	GIST 2 nd Line KIT Exon 11 + 17/18 (INSIGHT Phase 3 Study) ²	Phase 3 Planned for 2H 2023 ⁴						
Vimseltinib CSF1R Inhibitor	TGCT (MOTION Phase 3 Study)	Phase 3 Planned for 2H 2023 ⁴						
	TGCT (Phase 1/2 Study)	Phase 1/2 Planned for 2H 2023 ⁴						
DCC-3116 ULK Inhibitor	+ MEK Inhibitors (Trametinib or Binimetinib)	Phase 1/2 Planned for 2H 2023 ⁴						
	+ KRAS ^{G12C} Inhibitor (Sotorasib)	Phase 1/2 Planned for 2H 2023 ⁴						
	+ BRAF inhibitor / EGFR inhibitor (Encorafenib / Cetuximab)	Planned for 2H 2023 ⁴						
	+ KIT Inhibitor (Ripretinib)	Planned for 2H 2023 ⁴						
DCC-3084 Pan-RAF Inhibitor	Solid Tumors and Hematologic Malignancies	Planned for 2H 2023 ⁴						
DCC-3009 Pan-KIT Inhibitor	GIST	Planned for 1H 2024						
Additional Programs	GCN2	Phase 1/2 Planned for 2H 2023 ⁴						
	VPS34 ⁵	Phase 1/2 Planned for 2H 2023 ⁴						



Notes: BRAF=proto-oncogene b-RAF; CSF1R=colony-stimulating factor 1 receptor; EGFR=epidermal growth factor receptor; GCN2=general control nonderepressible 2; GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; MAPK=mitogen-activated protein kinase; RAF=rapidly accelerated fibrosarcoma; RAS=rat sarcoma gene; TGCT=tenosynovial giant cell tumor; ULK=unc-51-like autophagy-activating kinase; (1) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (2) The patient population for the planned INSIGHT study consists of second-line GIST patients with mutations in KIT exon 11 and 17 and/or 18 and the absence of mutations in KIT exon 9, 13, and/or 14 (also referred to as KIT exon 11 + 17/18 patients); (3) QINLOCK is approved for 4th line GIST in the United States, Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Switzerland, Taiwan, and the United Kingdom; (4) 2023 Corporate Goal; (5) Agreement with Sprint Bioscience for exclusive in-license worldwide rights to a research-stage program targeting VPS34.